Literature DB >> 12092657

K-RAS mutation in transitional cell carcinoma of urinary bladder.

S Ayan1, G Gokce, H Kilicarslan, O Ozdemir, E Yildiz, E Y Gultekin.   

Abstract

In the present study it was aimed to investigate the frequency of K-RAS mutation in the human bladder transitional cell carcinoma. For this purpose, tissue specimens obtained from the patients with bladder tumors. Genomic DNAs were isolated and then PCR-SSCP analysis of K-RAS gene were performed. A heterozygous deleted mutation was detected in K-RAS oncogene (exon 2) in agarose gel electrophoresis in one patient and point or substitution mutations are detected using single strand conformational polymorphism (SSCP) in other different patients with bladder cancer (4/14). In conclusion, the frequency of K-RAS mutation is not rare and the role of this mutation in oncogenesis and in infiltration of the urinary bladder wall needs to be confirmed in a larger study.

Entities:  

Mesh:

Year:  2001        PMID: 12092657     DOI: 10.1023/a:1015213713048

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  24 in total

Review 1.  The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee.

Authors:  J I Epstein; M B Amin; V R Reuter; F K Mostofi
Journal:  Am J Surg Pathol       Date:  1998-12       Impact factor: 6.394

Review 2.  Inositol lipids and cell proliferation.

Authors:  M J Berridge
Journal:  Biochim Biophys Acta       Date:  1987-04-20

3.  Detection of a rare point mutation in Ki-ras of a human bladder cancer xenograft by polymerase chain reaction and direct sequencing.

Authors:  S M Grimmond; D Raghavan; P J Russell
Journal:  Urol Res       Date:  1992

4.  KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas.

Authors:  V T Smit; A J Boot; A M Smits; G J Fleuren; C J Cornelisse; J L Bos
Journal:  Nucleic Acids Res       Date:  1988-08-25       Impact factor: 16.971

5.  H-RAS, K-RAS, and N-RAS gene activation in human bladder cancers.

Authors:  B Przybojewska; A Jagiello; P Jalmuzna
Journal:  Cancer Genet Cytogenet       Date:  2000-08

6.  Occupation, smoking, and the risk of high-grade invasive bladder cancer in Missouri.

Authors:  D R Brooks; A C Geller; J Chang; D R Miller
Journal:  Am J Ind Med       Date:  1992       Impact factor: 2.214

7.  Four human carcinoma cell lines with novel mutations in position 12 of c-K-ras oncogene.

Authors:  D M Valenzuela; J Groffen
Journal:  Nucleic Acids Res       Date:  1986-01-24       Impact factor: 16.971

8.  Concurrent mutations of coding and regulatory sequences of the Ha-ras gene in urinary bladder carcinomas.

Authors:  B Czerniak; G L Cohen; P Etkind; D Deitch; H Simmons; F Herz; L G Koss
Journal:  Hum Pathol       Date:  1992-11       Impact factor: 3.466

9.  A human gastric carcinoma contains a single mutated and an amplified normal allele of the Ki-ras oncogene.

Authors:  J L Bos; M Verlaan-de Vries; C J Marshall; G H Veeneman; J H van Boom; A J van der Eb
Journal:  Nucleic Acids Res       Date:  1986-02-11       Impact factor: 16.971

10.  Detection of ras gene mutations in human lung cancer: comparison of two screening assays based on the polymerase chain reaction.

Authors:  K Husgafvel-Pursiainen; M Ridanpää; P Hackman; S Anttila; A Karjalainen; A Onfelt; A L Børresen; H Vainio
Journal:  Environ Health Perspect       Date:  1992-11       Impact factor: 9.031

View more
  6 in total

1.  Time-dependent biological differences in molecular markers of high-grade urothelial cancer over 7 decades (ras proteins, pTEN, uPAR, PAI-1 and MMP-9).

Authors:  Jorunn Litlekalsoy; Jens G Hostmark; Daniela Elena Costea; Martin Illemann; Ole Didrik Laerum
Journal:  Virchows Arch       Date:  2012-10-06       Impact factor: 4.064

2.  Loss of heterozygosity of Kras2 gene on 12p12-13 in Chinese colon carcinoma patients.

Authors:  Jun Wan; Hong Li; Yuan Li; Mei-Ling Zhu; Po Zhao
Journal:  World J Gastroenterol       Date:  2006-02-21       Impact factor: 5.742

Review 3.  Management of bladder cancer: current and emerging strategies.

Authors:  Neeraj Agarwal; Maha Hussain
Journal:  Drugs       Date:  2009-06-18       Impact factor: 9.546

4.  Ras mutation cooperates with β-catenin activation to drive bladder tumourigenesis.

Authors:  I Ahmad; R Patel; Y Liu; L B Singh; M M Taketo; X-R Wu; H Y Leung; O J Sansom
Journal:  Cell Death Dis       Date:  2011-03-03       Impact factor: 8.469

5.  K-Ras and β-catenin mutations cooperate with Fgfr3 mutations in mice to promote tumorigenesis in the skin and lung, but not in the bladder.

Authors:  Imran Ahmad; Lukram Babloo Singh; Mona Foth; Carol-Ann Morris; Makoto Mark Taketo; Xue-Ru Wu; Hing Y Leung; Owen J Sansom; Tomoko Iwata
Journal:  Dis Model Mech       Date:  2011-04-18       Impact factor: 5.758

6.  Simultaneous activation of Kras and inactivation of p53 induces soft tissue sarcoma and bladder urothelial hyperplasia.

Authors:  Xiaoping Yang; Francisco G La Rosa; Elizabeth Erin Genova; Kendra Huber; Jerome Schaack; James Degregori; Natalie J Serkova; Yuan Li; Lih-Jen Su; Elizabeth Kessler; Thomas W Flaig
Journal:  PLoS One       Date:  2013-09-18       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.